Genomic and transcriptomic approaches reveal disease-specific risk genes (e.g., TREM2 in Alzheimer’s disease, ATXN2 in ALS) and biomarkers, enabling more precise diagnosis and personalized medicine [37]. This evidence concerns the gene TREM2 and amyotrophic lateral sclerosis.